CN106810549B - 7- azaindoles and its application containing dihydrogen dazin structure - Google Patents
7- azaindoles and its application containing dihydrogen dazin structure Download PDFInfo
- Publication number
- CN106810549B CN106810549B CN201611231832.XA CN201611231832A CN106810549B CN 106810549 B CN106810549 B CN 106810549B CN 201611231832 A CN201611231832 A CN 201611231832A CN 106810549 B CN106810549 B CN 106810549B
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxygroup
- pyrrolo
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title claims abstract description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims description 21
- -1 7-azaindole compound Chemical class 0.000 claims abstract description 133
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 201000005202 lung cancer Diseases 0.000 claims abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 4
- 201000007270 liver cancer Diseases 0.000 claims abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 4
- 230000002062 proliferating effect Effects 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 91
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 90
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 67
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 6
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004647 alkyl sulfenyl group Chemical group 0.000 claims description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 239000006071 cream Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 8
- 239000000651 prodrug Substances 0.000 abstract description 6
- 229940002612 prodrug Drugs 0.000 abstract description 6
- 239000002552 dosage form Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 239000003937 drug carrier Substances 0.000 abstract description 3
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical group N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 150000001989 diazonium salts Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 229940040145 liniment Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 2
- PKFDDUMFTQHVFY-UHFFFAOYSA-N 3-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC=C2C(Cl)=CNC2=N1 PKFDDUMFTQHVFY-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- ZNVXTQDRLJXJRW-UHFFFAOYSA-N 1h-pyridin-2-one;1h-pyrrolo[3,2-b]pyridine Chemical compound O=C1C=CC=CN1.C1=CC=C2NC=CC2=N1 ZNVXTQDRLJXJRW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FGMUTXIVAWGGAL-UHFFFAOYSA-N 4-(4-nitrophenoxy)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=NC2=C1C=CN2 FGMUTXIVAWGGAL-UHFFFAOYSA-N 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical class [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- SCBHTCDZDFMHBX-UHFFFAOYSA-N NC1=CC=CC=N1.C1=CC=C2NC=CC2=N1 Chemical compound NC1=CC=CC=N1.C1=CC=C2NC=CC2=N1 SCBHTCDZDFMHBX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- ZJTZRVZGAAUUFC-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(ON2C=CC=3C2=NC=CC3)C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(ON2C=CC=3C2=NC=CC3)C=C1 ZJTZRVZGAAUUFC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- KQWWVLVLVYYYDT-UHFFFAOYSA-N ethyl 3-oxohexanoate Chemical compound CCCC(=O)CC(=O)OCC KQWWVLVLVYYYDT-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含有二氢哒嗪结构的7‑氮杂吲哚类化合物、其几何异构体及其药学上可接受的盐、水合物、溶剂化物或前药，及其制备方法。本发明含有二氢哒嗪结构的7‑氮杂吲哚类化合物，及其药学上可接受的盐、水合物或溶剂化物作为活性成份，与药学上可接受的载体或赋型剂混合制备成组合物，并制备成临床上可接受的剂型。本发明化合物在制备治疗和/或预防增生性疾病药物中的应用，在制备治疗和/或预防癌症的药物中的应用，在制备治疗和/或预防肺癌、肝癌、胃癌、结肠癌、乳腺癌的药物中应用。 The invention discloses a 7-azaindole compound containing a dihydropyridazine structure, its geometric isomer, its pharmaceutically acceptable salt, hydrate, solvate or prodrug, and a preparation method thereof. The present invention contains 7-azaindole compounds of dihydropyridazine structure, and pharmaceutically acceptable salts, hydrates or solvates thereof as active ingredients, and is prepared by mixing with pharmaceutically acceptable carriers or excipients. composition, and prepared into a clinically acceptable dosage form. Application of the compound of the present invention in the preparation of medicines for the treatment and/or prevention of proliferative diseases, in the preparation of medicines for the treatment and/or prevention of cancer, in the preparation of medicines for the treatment and/or prevention of lung cancer, liver cancer, stomach cancer, colon cancer and breast cancer application in medicines.
Description
Technical field
The present invention relates to new Benzazole compounds, in particular to a kind of 7- Azaindoles containing dihydrogen dazin structure
Compound and its application.
Background technique
Malignant tumour is a kind of disease for seriously endangering human health and life.The death rate caused by human malignancies is only
Inferior to angiocarpy, it is arranged in second.The whole world is about diagnosed to be 10,000,000 tumor patients every year at present, and 7,000,000 people die of by swelling
Related disease caused by tumor, there are about 1,800,000 people to die of cancer, Zhan Quanqiu 1/4 every year for China.
C-Met kinases is hepatocyte growth factor receptor, is one of tyrosine kinase receptor family member, the c-Met of people
Gene is located at No. 7 chromosome long arm (7q31), and about 110kb contains 21 exons.Mature c-Met is by 5.0 × 104α it is sub-
Base and 1.4 × 105β subunit form heterodimer, extracellular region be α chain, intracellular region be β chain, two chains by disulfide bond be connected.
The phosphorylation of the Tyr1234 and Tyr1235 of region of activation can activate c-Met kinases.
C-Met kinases is widely present in epithelial tissue, is played an important role in embryonic development and wound healing.
Recent research indicate that c-Met kinases lung cancer, colon cancer, liver cancer, the carcinoma of the rectum, gastric cancer, kidney, oophoroma, glioma,
Abnormal high expression, mutation or activity change are presented in the tumor tissues such as melanoma, breast cancer, prostate cancer.C-Met kinases
The proliferation that can promote tumour cell adjusts the migration of tumour cell, enhances the invasive ability of tumour cell and induced tumor is new
The generation of angiogenic.
Currently, c-Met kinases has become an important target spot of anti-tumor drug research.Discovery oforally
active pyrrolopyridine-and aminopyridine-based Met kinase inhibitors.Bioorg.
Med.Chem.Lett.,2008,18,3224–3229；Discovery of Pyrrolopyridine-Pyridone Based
Inhibitors of Met Kinase:Synthesis,X-ray Crystallographic Analysis,and
The document reports such as Biological Activities.J.Med.Chem.2008,51,5330-5341 are one as shown in formula 1
The synthesis of serial 7- azaindoles and its pharmacology activity research show the c-Met kinases of the azaindole structure containing 7-
Inhibitor significantly inhibits malignant tumour.
In order to develop new and effective anti-tumor drug, the present inventor has carried out extensively 7- azaindoles
Multiple structural points are modified and are transformed, synthesized a series of 7- containing dihydrogen dazin structure of structure novels by research
Azaindole analog derivative.
Summary of the invention
It is an object of the invention to provide a kind of the 7- azaindoles containing dihydrogen dazin structure and its application.
7- azaindoles, its geometry that the present invention is provided as shown in general formula I containing dihydrogen dazin structure are different
Structure body and its pharmaceutically acceptable salt, hydrate, solvate or prodrug, general formula I are as follows:
Wherein:
R1For hydrogen, methyl, ethyl or cyano；
R2The hydrogen or fluorine identical or different selected from 1~4；
X is O or S；
R3、R4Hydrogen, halogen, (C are selected from for 1~21~C6) alkyl, (C1~C6) alkoxy, by halogenated (C1~C4) alkane
Base or (C1~C4) alkoxy, (C1~C6) alkyl sulfenyl, by single or double (C1~C6Alkyl) replace amino, (C1~C6) alkyl
Acylamino-, (C1~C6) alkyl sulphinyl, (C1~C6) alkyl acyl, by single or double (C1~C6Alkyl) replace carbamyl
Base, (C1~C3) alkylenedioxy group.
Present invention is preferably related to such as above-mentioned compounds of formula I, its geometric isomer or its pharmaceutically acceptable salt,
Hydrate, solvate or prodrug, in which:
R1For hydrogen or methyl；
R2For F, replace position by the ortho position on phenyl ring with X even carbon atom；
X is O；
R3For CH3Or CF3,
R4Fluorine, chlorine, methyl, methoxyl group, trifluoromethyl or trifluoromethoxy are selected from for 1~2.
In the present invention, the 7- azaindoles containing dihydrogen dazin structure of the general formula I are particularly preferably following
One of compound, but these compounds are not meant to any limitation of the invention:
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- phenyl -1,6-
Dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (adjacent toluene
Base) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (3- fluorophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (4- fluorophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2,4 dichloro benzene base) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (the bromo- 2- fluorophenyl of 4-) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoro
Methyl) phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoro
Methoxyl group) phenyl) -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(o-tolyl) -1,6- dihydrogen dazin -3- formamide,
1- (2,5- 3,5-dimethylphenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygen
Base) phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (4- fluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (3,4- difluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup)
Phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (the bromo- 2- fluorophenyl of 4-) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygen
Base) phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (3- bromophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(2- (trifluoromethoxy) phenyl) -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(4- methoxyl group) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2,5- 3,5-dimethylphenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2- fluorophenyl) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3,4- difluorophenyl) -4-
Methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (the chloro- 4- fluorophenyl of 3-) -4-
Methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3- bromophenyl) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (2-
(trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (4-
(methoxyl group) -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- phenyl -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2- fluorophenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (3- fluorophenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (the chloro- 4- fluorophenyl of 3-)-N- (fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup)
Phenyl) -4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (2,4 dichloro benzene base)-N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- (2- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- (3- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide.
Moreover, according to some usual methods of the art, general formula I of the present invention containing dihydrogen dazin structure
7- azaindoles can generate its pharmaceutically acceptable salt with acid.Acid may include inorganic acid or organic acid,
The salt formed with following acid is particularly preferred: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzene
Sulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, Tartaric acid, benzene sulfonic acid, benzene first
Acid or p-methyl benzenesulfonic acid etc..
In addition, the invention also includes the prodrugs of the compounds of this invention.According to the present invention, prodrug is spreading out for compound of Formula I
Biology, their own may have weaker activity or even without activity, but upon administration, in physiological conditions (such as
Pass through metabolism, solvolysis or other mode) it is converted to corresponding biologically active form.
Unless otherwise noted, term used herein " halogenated " refers to fluoro, chloro, bromo or iodo；" alkyl " is
Refer to the alkyl of linear chain or branched chain；" naphthenic base " refers to substituted or unsubstituted naphthenic base；" alkenyl " refers to the alkene of linear chain or branched chain
Base；" alkynyl " refers to the alkynyl of linear chain or branched chain；" aryl " refers to organic group obtained by the hydrogen atom removed in aromatic hydrocarbons,
Such as phenyl, naphthalene；5-10 unit's heteroaryl includes the hetero atoms that N, O and S are selected from containing one or more, wherein each heteroaryl
Cyclic annular system can be monocycle or polycyclic, and cyclic annular system is armaticity, contain 5-10 atom altogether, it can be cited for example that
Imidazole radicals, pyridyl group, pyrimidine radicals, pyrazolyl, (1,2,3) and (1,2,4)-triazolyl, pyrazinyl, tetrazole radical, furyl, thiophene
Base, isoxazolyl, oxazolyl, pyrazolyl, pyrrole radicals, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzo
Thiazolyl, indyl, quinolyl etc.；5-10 circle heterocyclic ring base includes the hetero atoms that N, O and S are selected from containing one or more, wherein
The cyclic annular system of each heteroaryl can be monocycle or polycyclic, but be it is nonaromatic, cyclic annular system contains 5-10 altogether
A atom can include optionally 1 or 2 carbon-carbon double bond or carbon-carbon triple bond, it can be cited for example that pyrrolidinyl, morpholinyl, piperazine
Base, piperidyl, thiazolinyl etc..
Synthetic route 1~3 describes the preparation of compound of Formula I of the invention below, and all raw materials are all to pass through this
Method described in a little chemical formulas, by organic chemistry filed method preparation well-known to the ordinarily skilled artisan or commercially available.
Whole final compounds of the invention are prepared by method described in these chemical formulas or by similar method
, these methods are that organic chemistry filed is well-known to the ordinarily skilled artisan.The whole variable factors applied in these chemical formulas are such as
Definition hereafter or such as the definition in foregoing teachings.
Compound of Formula I according to the invention, X, R1、R2、R3And R4If foregoing teachings part defines, the road Jun Kean
The method of line 1 is made by intermediate A and intermediate B by substitution reaction.
Compound of formula I according to the invention, X O, other substituent groups such as foregoing teachings are defined, the preparation side of intermediate A
Method is as shown in Scheme 2:
When X is S, the preparation of compound A can be by the intermediate a and R of route 22Substituted 4- nitro thiophenol is substituted,
Two-step reaction is restored to be made.
Type I compound according to the invention, the preparation method of intermediate B such as route 3, other substituent groups such as foregoing teachings institute
Definition.
The substituent R of all intermediates in above three routes1、R2、R3、R4As defined in foregoing teachings.
The present invention can contain the 7- azaindoles and its pharmacy of dihydrogen dazin structure containing above-mentioned general formula I
Upper acceptable salt, hydrate or solvate mix system with pharmaceutically acceptable carrier or excipients as active ingredient
Standby and to be prepared into clinically acceptable dosage form at composition, above-mentioned pharmaceutically acceptable excipients refer to any can be used for
Diluent, adjuvant and/or the carrier of pharmaceutical field.Derivative of the invention can be applied in combination with other active ingredients, only
Them are wanted not generate other unfavorable effects, such as allergic reaction.
The 7- azaindoles that the above-mentioned general formula I of the present invention contains dihydrogen dazin structure are used for the clinical dosage of patient
It can basis: the year of active constituent therapeutic efficiency in vivo and bioavilability, their metabolism and discharge rate and patient
Age, gender, disease phase carry out appropriate adjustment, but adult daily dosage generally should be 10~500mg, preferably 50~
300mg.Therefore, when pharmaceutical composition of the invention is made into unit dosage forms, it is contemplated that above-mentioned effective dose, per unit preparation
It should contain the 7- azaindoles of dihydrogen dazin structure containing the above-mentioned general formula I of 10~500mg, preferably 50~
300mg.According to the guidance of doctor or pharmacist, these preparations can divide at certain intervals is administered (preferably one to six several times
It is secondary).
Pharmaceutical composition of the invention can be configured to several dosage form, wherein containing some common figurations in drug field
Agent.Several dosage form as described above can be using injection, tablet, capsule, aerosol, suppository, film, pill, outer
With drug forms such as liniment, ointments.
Carrier for pharmaceutical composition of the present invention is available common type in drug field, comprising: adhesive, profit
Lubrication prescription, disintegrating agent, cosolvent, diluent, stabilizer, suspending agent, non-pigment, corrigent, preservative, solubilizer and matrix etc..
Pharmaceutical preparation can by oral administration or parenteral (such as in intravenous, subcutaneous, peritonaeum or part) is administered, if some drugs
It is unstable under the conditions of stomach, enteric coated tablets can be configured to.
Have the function of strong inhibition c-Met kinases the invention further relates to compounds of formula I, and further relates to such change
Object and its pharmaceutically acceptable salt, hydrate, solvate or prodrug are closed in preparation treatment due to the extremely high table of c-Met kinases
Purposes up in the drug of diseases caused, the especially purposes in the drug of preparation treatment and/or pre- anti-cancer.
Reactive compound of the invention or its officinal salt and its solvate can be used as unique anti-proliferate drug list
Solely use, or can with the anti-proliferate Drug combination that has listed, for treating and/or preventing proliferative disease,
Such as psoriasis, benign prostatauxe, atherosclerosis and restenosis.
It has also been found that the above-mentioned 7- azaindoles containing dihydrogen dazin structure are in preparation treatment and/or in advance
Application in the drug of anti-cancer.The compounds of this invention has inhibition tumor cell growth activity in vitro, and therefore, it may be used as
The drug of preparation treatment and/or pre- anti-cancer, such as mammary gland, lung, liver, kidney, colon, rectum, stomach, prostate, bladder, son
Palace, pancreas, marrow, testis, ovary, lymph, soft tissue, neck, thyroid gland, the cancer of esophagus and leukaemia, neuroblastoma
Deng.
It being found by testing c-Met kinase activity, the compounds of this invention has significant inhibition c-Met kinase activity,
There is stronger inhibiting effect to the highly expressed lung cancer of c-Met, liver cancer, gastric cancer, colon cancer, breast cancer etc., it is especially useful in preparation is controlled
Treat and/or prevent the drug of lung cancer.
It is independent that reactive compound of the invention or its officinal salt and its solvate can be used as unique anti-tumor drug
It uses, or can be with the anti-tumor drug (such as the platinum medicine cis-platinum, camptothecine Irinotecan, Changchun that have listed
Flower bases drug Noviburn, deoxidation born of the same parents' former times class drug gemcitabine, etoposide, taxol etc.) it is used in combination.Combination therapy is logical
Cross each therapeutic component simultaneously, sequence or separate administration to realize.
Specific embodiment
In order to better explain the present invention, below in conjunction with specific embodiment, the present invention is described in further detail, but
Limiting the invention for they.
Embodiment is intended to illustrate and be not intended to limit the scope of the invention.The nuclear magnetic resonance spectroscopy BrukerARX- of compound
300 measurements, mass spectrum are measured with Agilent1100LC/MSD；Agents useful for same is that analysis is pure or chemical pure.
General formula I contains the 7- azaindoles of dihydrogen dazin structure:
0 compound of Examples 1 to 3, structural formula such as the following table 1 institute is made according to the method for preparing general formula I in the present invention respectively
Show.
The structural formula of 1 Examples 1 to 30 of table
Embodiment 1
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- phenyl -1,6-
Dihydrogen dazin -3- formamide
Step 1: 4- (4-nitrophenoxy) -1H- pyrrolo- [2,3-b] pyridine (b)
In the three-necked bottle of 250mL, diphenyl ether (51.843g, 0.3mol) is preheated to whole dissolutions, is then sequentially added
The chloro- 7- azaindole (9.996g, 0.066mol) of 4- and 4- nitrophenol (16.862g, 0.107mol) are warming up to 190 DEG C instead
Should about 1h, during which having a large amount of solids can not stir, when temperature rises to 130 DEG C or so solid dissolve, solution present it is faint yellow, with
Temperature increases, and solution colour is deepened, and appearance is dark brown, is still faint yellow when sampling contact plate.After reaction solution is cooling, it is slowly added dropwise
2h is stirred into 400mL ethyl acetate, the solid of precipitation filters, and filtration cakes torrefaction obtains khaki powder 8.285g, i.e. 4- (4- nitre
Phenoxyl) -1H- pyrrolo- [2,3-b] pyridine (b), yield 46.3%.
Step 2: 4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl oxygroup) aniline (A)
By 4- made from step 1 (4-nitrophenoxy) -1H- pyrrolo- [2,3-b] pyridine (b) (5.102g,
It 0.0187mol) adds to ethyl alcohol (100mL), ferric trichloride (2.687g, 0.00994mol) and activity is sequentially added under stirring condition
Hydrazine hydrate (9.445g, 0.1887mol) is added dropwise in charcoal (8.440g, 0.703mol) when being warming up to 50 DEG C or so.It is added dropwise to complete
After be warming up to 80 DEG C of reflux about 10min.Reaction solution is cooling, filters, filtrate revolving, and after being evaporated plus 75mL water is ultrasonic, is precipitated a large amount of
Yellow solid filters, and yellow powder 2.432g, i.e. 4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl oxygroup) are obtained after filtration cakes torrefaction
Aniline (A), yield 53.6%.
Step 3: along ethyl -3- oxo -2- (Phenylhydrazono) ethyl butyrate (e)
In the there-necked flask of 500mL be added 50mL water and 200mL alcohol mixed solution, be added anhydrous sodium acetate stir to
Ethyl acetoacetate is added after dissolution, 2h is stirred at room temperature, it is spare.Aniline and 50mL water, room are added in another 250mL there-necked flask
Temperature is lower to be added dropwise concentrated hydrochloric acid, and the aqueous solution of sodium nitrite is added dropwise in drop when being cooled to -5 DEG C after finishing, keep solution temperature to be lower than 0 DEG C, drop
30min is reacted at 0 DEG C after finishing, a small amount of water is added if having solid in solution, so that diazonium salt solution keeps clarification.By second
The mixed solution of ethyl acetoacetic acid ethyl ester is cooled to solution temperature at 0 DEG C hereinafter, loading onto mechanical stirring, and above-mentioned resulting diazonium salt is molten
Liquid is slowly dropped into, keep solution temperature at 0 DEG C hereinafter, with diazonium salt solution instillation, have a large amount of yellow in reaction solution
Solid generate, drop finish after add 100mL water, after in 0 DEG C or less reaction 2h.Yellow solid obtained in above-mentioned reaction solution is taken out
Filter, filter cake are washed with water, dry, obtain 17g product, i.e., along ethyl -3- oxo -2- (Phenylhydrazono) ethyl butyrate (e), receive
Rate about 95% or more.
Step 4: ethyl -4- methyl -6- oxo -1- phenyl -1,6- dihydrogen dazin -3- carboxylic acid, ethyl ester (f)
By intermediate e (5g, 0.033mol) made from step 3, carbethoxymethylene triphenyl phosphorus (9.39g,
0.027mol) and Et2NH (0.28mL, 0.0027mol) is added in DMSO at room temperature, is warming up to 85 DEG C of reaction 4h.It is intermediate
Body e reaction is endless.Reaction solution is cooled to during room temperature falls back, is extracted with DCM, organic layer uses saturated common salt water washing again
Three times, anhydrous sodium sulfate is dry.It filters, is evaporated DCM and obtains brown oil, obtain ethyl -4- methyl -6- oxo -1- phenyl -
1,6- dihydrogen dazin -3- carboxylic acid, ethyl ester (f), yield 85%.
Step 5: ethyl -4- methyl -6- oxo -1- phenyl -1,6- dihydrogen dazin -3- carboxylic acid (g)
Intermediate f is dissolved in 50mL ethyl alcohol, 10%NaOH is added dropwise at room temperature and makes the pH value of solution to after 12, is warming up to
60 DEG C of reaction 4h.The most of a large amount of water of addition, aqueous solution later is evaporated off in reaction solution to be extracted with ethyl acetate, separates water layer,
The water layer dilute hydrochloric acid of 6M adjusts pH value to after 2~3, and with DCM aqueous layer extracted, DCM solution is dried, filtered with anhydrous sodium sulfate,
Yellow solid, i.e. ethyl -4- methyl -6- oxo -1- phenyl -1,6- dihydrogen dazin -3- carboxylic acid (g), yield are obtained after concentration
70%.
Step 6: ethyl -4- methyl -6- oxo -1- phenyl -1,6- dihydrogen dazin -3- formyl chloride (B)
Intermediate g (0.01mol) is added in the toluene of 30mL, SOCl is added2(6mL) and pyridine (5d) are warming up to 85
DEG C reaction 6h.After reaction solution is cooled to room temperature, toluene and SOCl are removed under reduced pressure2, obtain oily liquids acyl chlorides, i.e. ethyl-
4- methyl -6- oxo -1- phenyl -1,6- dihydrogen dazin -3- formyl chloride (B), yield 50%
Step 7: N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- benzene
Base -1,6- dihydrogen dazin -3- formamide
Intermediate A (0.05g, 0.00021mol) and n,N-diisopropylethylamine (0.5mL, 0.003mol) are added into 10mL
In methylene chloride, intermediate B (0.2g, 0.00073mol) is dissolved in 5mL methylene chloride, above-mentioned dichloromethane is added dropwise at 0 DEG C
It in alkane solution, is added dropwise, is slowly increased to room temperature, react 1~2 hour.After completion of the reaction, the sodium hydroxide water of 5mL5% is added
Aqueous solution stirs half an hour, is transferred in 250mL separatory funnel, adds 25mL methylene chloride, use saturated aqueous sodium carbonate
It washes (50mL*3) three times, saturated common salt washing is primary, depressurizes steaming vibrating dichloromethane, obtains faint yellow solid powder 0.05g, yield
46.14%.
ESI-MS m/z:532.1；1H NMR(300MHz,DMSO-d6)δ12.22(s,1H),11.56(s,1H),9.04
(s, 1H), 8.26 (s, 1H), 7.79 (d, J=6.8Hz, 2H), 7.63 (d, J=7.8Hz, 1H), 7.56 (d, J=7.0Hz,
2H), 7.40 (s, 2H), 7.20 (d, J=8.8Hz, 2H), 6.94 (s, 1H), 6.66 (s, 1H), 6.61 (s, 1H), 2.68 (s,
3H).
According to the method for embodiment 1, first with R1The chloro- 7- azaindole of substituted 4- and R2Substituted 4- nitrophenol, warp
Step 1 replaces, step 2 reduction reaction obtains intermediate A；R4Substituted aniline elder generation diazotising again with R3Substituted acetoacetate
Ethyl ester obtains intermediate B through step 3 even summation, step 4 cycloaddition, step 5 hydrolysis, step 6 acyl chloride reaction；Later in
2~30 compound of embodiment is made by step 7 substitution reaction in mesosome A and intermediate B respectively.
Embodiment 2
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (adjacent toluene
Base) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:451.2；1H NMR(300MHz,DMSO-d6)δ12.20(s,1H),11.64(s,1H),8.23
(d, J=6.3Hz, 1H), 7.71 (d, J=6.7Hz, 2H), 7.48-7.37 (m, 3H), 7.32 (d, J=6.7Hz, 2H), 7.14
(s, 1H), 6.99 (s, 1H), 6.95 (s, 1H), 6.71 (d, J=4.6Hz, 1H), 6.61 (s, 1H), 2.70 (s, 1H), 2.22
(s,1H).
Embodiment 3
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (3- fluorophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:455.1.
Embodiment 4
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (4- fluorophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:455.1.
Embodiment 5
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2,4 dichloro benzene base) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:505.1；1H NMR(300MHz,DMSO-d6)δ12.64(s,1H),11.64(s,1H),8.25
(s, 1H), 7.78 (d, J=7.5Hz, 2H), 7.63 (s, 1H), 7.46-7.38 (m, 2H), 7.21 (d, J=7.2Hz, 2H),
7.17 (s, 1H), 6.95 (s, 1H), 6.65 (d, J=6.7Hz, 1H), 6.61 (s, 1H), 2.70 (s, 3H)
Embodiment 6
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (the bromo- 2- fluorophenyl of 4-) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:533.1.
Embodiment 7
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoro
Methyl) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:505.1.
Embodiment 8
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoro
Methoxyl group) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:521.1；1H NMR(300MHz,DMSO-d6)δ12.70(s,1H),12.04(s,1H),8.18
(d, J=9.5Hz, 1H), 7.99 (d, J=6.5Hz, 1H), 7.70 (d, J=7.7Hz, 1H), 7.61 (d, J=6.5Hz, 2H),
7.54 (d, J=6.6Hz, 1H), 7.49 (d, J=8.3Hz, 2H), 7.37 (s, 1H), 7.23 (d, J=7.5Hz, 2H), 6.73
(d, J=5.2Hz, 1H), 6.52 (s, 1H), 2.28 (s, 3H)
Embodiment 9
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(o-tolyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:465.2.
Embodiment 10
1- (2,5- 3,5-dimethylphenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygen
Base) phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:480.2
Embodiment 11
1- (4- fluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:469.2；1H NMR(300MHz,DMSO-d6)δ12.07(s,1H),8.97(s,1H),7.82(d,
J=10.4Hz, 2H), 7.63 (d, J=7.6Hz, 2H), 7.54 (d, J=6.1Hz, 2H), 7.08 (t, J=8.3Hz, 2H),
6.94(s,1H),6.87(s,1H),6.67(s,1H),6.62(s,1H),4.34(s,3H),2.51(s,3H).
Embodiment 12
1- (3,4- difluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup)
Phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:487.1.
Embodiment 13
1- (the bromo- 2- fluorophenyl of 4-) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygen
Base) phenyl) -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:547.1；1H NMR(300MHz,DMSO-d6) δ 10.64 (s, 1H), 8.13 (d, J=5.4Hz,
1H), 7.85 (d, J=9.7Hz, 1H), 7.78 (d, J=8.8Hz, 2H), 7.71-7.63 (m, 2H), 7.41 (d, J=3.3Hz,
1H), 7.20 (d, J=8.8Hz, 2H), 7.10 (s, 1H), 6.45 (d, J=5.4Hz, 1H), 6.18 (d, J=3.4Hz, 1H),
3.80(s,3H),2.40(s,3H).
Embodiment 14
1- (3- bromophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:529.1.
Embodiment 15
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(2- (trifluoromethoxy) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:535.1.
Embodiment 16
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1-
(4- methoxyl group) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:481.2.
Embodiment 17
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2,5- 3,5-dimethylphenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:483.2.
Embodiment 18
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2- fluorophenyl) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:473.1；1H NMR(300MHz,DMSO-d6)δ12.39(s,1H),10.90(s,1H),8.21
(d, J=5.7Hz, 1H), 8.11 (d, J=3.6Hz, 1H), 8.00 (d, J=12.8Hz, 1H), 7.75 (d, J=11.7Hz,
1H), 7.57-7.43 (m, 3H), 7.34 (d, J=8.2Hz, 2H), 7.15 (s, 1H), 6.91 (d, J=4.2Hz, 1H), 6.70
(d, J=5.4Hz, 1H), 2.47 (s, 3H)
Embodiment 19
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3,4- difluorophenyl) -4-
Methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:491.1；1H NMR(300MHz,DMSO-d6)δ12.34(s,1H),11.76(s,1H),9.17
(s, 1H), 8.21 (d, J=12.6Hz, 1H), 7.94 (d, J=13.4Hz, 1H), 7.56 (d, J=8.2Hz, 1H), 7.43 (d, J
=7.9Hz, 2H), 7.32 (d, J=7.9Hz, 2H), 6.87 (s, 1H), 6.68 (d, J=13.3Hz, 1H), 6.55 (s, 1H),
2.55(s,3H).
Embodiment 20
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (the chloro- 4- fluorophenyl of 3-) -4-
Methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:507.1.
Embodiment 21
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3- bromophenyl) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:533.1.
Embodiment 22
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (2-
(trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:523.2；1H NMR(300MHz,DMSO-d6)δ12.83(s,1H),12.16(s,1H),8.12-
8.04 (m, 3H), 7.89 (d, J=7.6Hz, 1H), 7.80 (s, 1H), 7.75 (d, J=7.5Hz, 1H), 7.63 (d, J=
10.6Hz, 1H), 7.54 (d, J=9.4Hz, 1H), 7.40 (s, 1H), 7.31 (d, J=8.3Hz, 1H), 6.72 (d, J=
5.7Hz,1H),6.57(s,1H),2.26(s,3H).
Embodiment 23
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (4-
(methoxyl group) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:485.2.
Embodiment 24
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- phenyl -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:469.2.
Embodiment 25
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2- fluorophenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:487.1.
Embodiment 26
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (3- fluorophenyl) -
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:487.1.
Embodiment 27
1- (the chloro- 4- fluorophenyl of 3-)-N- (fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup)
Phenyl) -4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:521.1.
Embodiment 28
1- (2,4 dichloro benzene base)-N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:537.1.
Embodiment 29
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- (2- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:537.1.
Embodiment 30
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxygen
Generation -1- (3- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide
ESI-MS m/z:537.1；1H NMR(300MHz,DMSO-d6)) δ 12.82 (s, 1H), 8.29 (d, J=5.0Hz,
1H), 8.08 (d, J=12.1Hz, 2H), 7.89 (d, J=7.6Hz, 1H), 7.84-7.72 (m, 2H), 7.63 (d, J=7.8Hz,
1H), 7.54 (d, J=7.0Hz, 1H), 7.30 (s, 1H), 7.20 (d, J=1.7Hz, 1H), 6.71 (d, J=6.1Hz, 1H),
6.65(s,1H),4.31(s,3H),2.26(s,3H).
The pharmacological research of product of the present invention
Extracorporeal anti-tumor cell activity
External suppression has been carried out to the 7- azaindoles containing dihydrogen dazin structure of general formula I according to the invention
Lung carcinoma cell H460, colon cancer cell HT-29, gastric carcinoma cells MKN-45, human umbilical vein endothelial cell and bladder cancer cell U- processed
87MG screening active ingredients.
(1) after 2~3 stabilizations of cell recovery and passage, make it from culture bottle bottom with trypsin solution (0.25%)
Digestion is got off.After cell dissociation buffer is poured into centrifuge tube, culture solution is added later to terminate digestion.By centrifuge tube in 800r/
It is centrifuged 10min under min, 5mL culture solution is added after discarding supernatant liquid, piping and druming mixes cell, draws 10 μ L cell suspensions and is added
It is counted in cell counting board, adjustment cell concentration is 104A/hole.Except the hole A1 is that blank well is not added extracellularly in 96 orifice plates, remaining
100 μ L cell suspensions are all added.96 orifice plates are put into incubator and are cultivated for 24 hours.
(2) with 50 μ L dmso solution given the test agent, appropriate culture solution is then added, sample is made to be dissolved into 2mg/mL
Then sample is diluted to 20,4,0.8,0.16,0.032 μ g/mL in 24 orifice plates by medical fluid.
3 holes are added in each concentration, wherein surrounding two rows, two column cell growing way is affected by environment larger, it only and is blanc cell
Hole uses.96 orifice plates are put into incubator and cultivate 72h.
(3) band medicine culture solution in 96 orifice plates is discarded, is rinsed cell twice with phosphate buffer solution (PBS), in every hole
Middle 100 μ L of addition MTT (tetrazole) (0.5mg/mL) is put into incubator after 4h, discards MTT solution, and dimethyl sulfoxide is added
100μL.Oscillation dissolves survivaling cell sufficiently with MTT reaction product formazan on magnetic force oscillator, is put into microplate reader and measures
As a result.Drug IC can be found out by Bliss method50Value.
Inhibition lung carcinoma cell H460, colon cancer cell HT-29, the gastric carcinoma cells MKN-45, lung adenocarcinoma cell of compound
A549 and bladder cancer cell U-87MG Activity Results are as shown in table 2.
The test of c-Met enzymatic activity
Test for measuring c-Met kinase activity is based on enzyme-linked immunosorbent assay (ELISA).Concrete operations are:
At room temperature, on the coated plate of 0.25mg/mL PGT, by embodiment compound, 50pM c-Met, (His- is marked
Recombined human Met (end amino acid 974-), by baculovirus expression and 5 μM of ATP in test buffer (25mM MOPS,
pH 7.4,5mM MgCl2,0.5raM MnCl2, 100 μM of sodium orthovanadates, 0.01%TritonX-100,1mM DTT, last DMSO
Concentration 1% (v/v)) it incubates 20 minutes.By rinsing removing reaction mixture and horseradish peroxidase being conjugated with 0.2 μ g/mL
(HRP) phosphotyrosine monoclonal antibody specific (PY20) detects phosphorylated polymer substrate.It is aobvious that the termination of 1M phosphoric acid is added
After color, pass through the color of the substrate (TMB) of spectrophotometry quantitative chromogenic at 450nm.Embodiment compound is to c-Met kinases
Inhibition data it is as shown in table 2.
Table 2:
From above-mentioned test result it can be clearly seen that the compound of the claimed general formula I of the present invention, has good
Anti tumor activity in vitro, quite or better than the anti-tumor drug cis-platinum listed.
The compound of formula of I of the present invention can be administered alone, but usually give with pharmaceutical carrier mixture, described medicinal
The selection of carrier will be according to required route of administration and standard pharmaceutical practice, separately below with the various drug agent of such compound
Type, such as the preparation method of tablet, capsule, injection, aerosol, suppository, film, pill, externally-applied liniment and ointment,
Illustrate its new opplication in pharmaceutical field.
Application examples 1: tablet
100 are pressed into, often after adding auxiliary material 20g to mix according to the general pressed disc method of pharmacy with 1 compound 10g of embodiment
Slice weight 300mg.
Application examples 2: capsule
With 10 compound 10g of embodiment be packed into hollow glue after auxiliary material 20g being mixed according to the requirement of pharmacy capsule
Capsule, each capsule weight 300mg.
Application examples 3: injection
Activated carbon adsorption is carried out according to pharmacy conventional method with 13 compound 10g of embodiment, is filtered through 0.65 μm of micropore
After film filtering, hydro-acupuncture preparation is made in filling nitrogen gas tank, and every dress 2mL is filling 100 bottles total.
Application examples 4: aerosol
It after distilled water and other spoke material are added, is made after the dissolution of appropriate propylene glycol with 20 compound 10g of embodiment
The clear solution of 500mL to obtain the final product.
Application examples 5: suppository
With 19 compound 10g of embodiment, by finely ground addition glycerol it is appropriate, the glycerin gelatine melted is added after grinding well,
Grinding uniformly, is poured into the model for having applied lubricant, and suppository 50 is made.
Application examples 6: film
With 28 compound 10g of embodiment, will be dissolved by heating after the stirrings such as polyvinyl alcohol, medicinal glycerin, water expansion, 80 meshes
Net filtration, then 18 compound of embodiment is added to stirring and dissolving in filtrate, film applicator is film-made 100.
Application examples 7: pill
It is instilled in cryogenic liquid paraffin after being mixed with matrix 50g heating fusings such as gelatin with 17 compound 10g of embodiment,
1000 ball of dripping pill is made altogether.
Application examples 8: externally-applied liniment
With 21 compound 10g of embodiment, according to the auxiliary materials 2.5g mixed grinding such as conventional dose method and emulsifier, then plus
Distilled water is obtained to 200mL.
Application examples 9: ointment
With 26 compound 10g of embodiment, ground well after finely ground with oleaginous bases 500g such as vaseline obtained.
Although describing the present invention by specific embodiment, modification and equivalent variations are for being proficient in this field
It will be apparent from for technical staff, and they are included within the scope of the invention.
Claims (7)
1. a kind of 7- azaindoles containing dihydrogen dazin structure, which is characterized in that structure such as the following general formula I institute
Show:
Wherein:
R1For hydrogen, methyl, ethyl or cyano；
R2The hydrogen or fluorine identical or different selected from 1~4；
X is O or S；
R3 be selected from hydrogen, halogen, (C1~C6) alkyl, (C1~C6) alkoxy, by halogenated (C1~C4) alkyl or (C1~C4)
Alkoxy, (C1~C6) alkyl sulfenyl, the amino replaced by single or double (C1~C6 alkyl), (C1~C6) alkyl amido, (C1
~C6) alkyl sulphinyl, (C1~C6) alkyl acyl, by single or double (C1~C6 alkyl) replace carbamoyl in 1
It is a；
R4 be 1~2 selected from hydrogen, halogen, (C1~C6) alkyl, (C1~C6) alkoxy, by halogenated (C1~C4) alkyl or
(C1~C4) alkoxy, (C1~C6) alkyl sulfenyl, the amino replaced by single or double (C1~C6 alkyl), (C1~C6) alkyl acyl
Amino, (C1~C6) alkyl sulphinyl, (C1~C6) alkyl acyl, the carbamyl replaced by single or double (C1~C6 alkyl)
Base, (C1~C3) alkylenedioxy group.
2. the 7- azaindoles containing dihydrogen dazin structure according to claim 1, it is characterised in that:
R1For hydrogen or methyl；
R2For F, replace position by the ortho position on phenyl ring with X even carbon atom；
X is O；
R3For CH3Or CF3,
R4Fluorine, chlorine, methyl, methoxyl group, trifluoromethyl or trifluoromethoxy are selected from for 1~2.
3. the 7- azaindoles containing dihydrogen dazin structure according to claim 1, it is characterised in that: described logical
The compound of Formulas I is selected from one of following compounds:
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- phenyl -1,6- dihydro
Pyridazine -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (o-tolyl) -1,
6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) oxo-1-1- (3- fluorophenyl)-4- methyl-6-,
6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) oxo-1-1- (4- fluorophenyl)-4- methyl-6-,
6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2,4 dichloro benzene base) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (the bromo- 2- fluorophenyl of 4-) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoromethyl)
Phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1- (3- (trifluoro methoxy
Base) phenyl) -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1- (adjacent first
Phenyl) -1,6- dihydrogen dazin -3- formamide,
1- (2,5- 3,5-dimethylphenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (4- fluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -
6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (3,4- difluorophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (the bromo- 2- fluorophenyl of 4-) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (3- bromophenyl) -4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6-
Oxo -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1- (2- (three
Fluorine methoxyl group) phenyl) -1,6- dihydrogen dazin -3- formamide,
4- methyl-N- (4- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -6- oxo -1- (4- first
Oxygroup) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2,5- 3,5-dimethylphenyl) -4- first
Base -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (2- fluorophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3,4- difluorophenyl) -4- methyl -
6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (the chloro- 4- fluorophenyl of 3-) -4- first
Base -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -1- (3- bromophenyl) -4- methyl -6- oxygen
Generation -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (2- (trifluoro
Methyl) phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (4- ((1H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) -3- fluorophenyl) -4- methyl -6- oxo -1- (4- (methoxy
Base) -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1-
Phenyl -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (2- fluorophenyl) -4- first
Base -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -1- (3- fluorophenyl) -4- first
Base -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (the chloro- 4- fluorophenyl of 3-)-N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) benzene
Base) -4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
1- (2,4 dichloro benzene base)-N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl)-
4- methyl -6- oxo -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1-
(2- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide,
N- (the fluoro- 4- of 3- ((1- methyl-1 H- pyrrolo- [2,3-b] pyridin-4-yl) oxygroup) phenyl) -4- methyl -6- oxo -1-
(3- (trifluoromethyl) phenyl) -1,6- dihydrogen dazin -3- formamide.
4. a kind of pharmaceutical composition, comprising compound described in one of claims 1 to 3 and its pharmaceutically acceptable salt as work
Property ingredient and pharmaceutically acceptable excipients.
5. application of the pharmaceutical composition in preparation treatment and/or prevention proliferative disease drug according to claim 4.
6. application of the pharmaceutical composition in the drug of preparation treatment and/or pre- anti-cancer according to claim 4.
7. pharmaceutical composition is in preparation treatment and/or prevention lung cancer, liver cancer, gastric cancer, colon cancer, cream according to claim 4
Application in the drug of gland cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611231832.XA CN106810549B (en) | 2016-12-28 | 2016-12-28 | 7- azaindoles and its application containing dihydrogen dazin structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611231832.XA CN106810549B (en) | 2016-12-28 | 2016-12-28 | 7- azaindoles and its application containing dihydrogen dazin structure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106810549A CN106810549A (en) | 2017-06-09 |
| CN106810549B true CN106810549B (en) | 2019-05-24 |
Family
ID=59110260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611231832.XA Active CN106810549B (en) | 2016-12-28 | 2016-12-28 | 7- azaindoles and its application containing dihydrogen dazin structure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106810549B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109096250A (en) * | 2018-09-25 | 2018-12-28 | 辽宁大学 | 4- phenoxypyridines class compound and its application containing pyridazinone |
| CN111533735A (en) * | 2020-05-08 | 2020-08-14 | 张建蒙 | Oxo-dihydropyridazine thiazole derivative and application thereof in antitumor drugs |
-
2016
- 2016-12-28 CN CN201611231832.XA patent/CN106810549B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors;Zhen-Wei Cai et al.;《Bioorganic & Medicinal Chemistry Letters》;20080425;第18卷;3224-3229 |
| Discovery of Pyrrolopyridine-Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities;Kyoung Soon Kim et al.;《J. Med. Chem.》;20081231;第51卷;5330-5341 |
| Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress;J. Jean Cui;《J. Med. Chem.》;20130909;第57卷;4427-4453 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106810549A (en) | 2017-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6087954B2 (en) | Quinolines and cinnolines compounds and uses thereof | |
| JP7109919B2 (en) | USP7 inhibitor compounds and methods of use | |
| BR112013018212A2 (en) | DIETARY HYDRAZIDE ACETYLENE CONTAINING TYROSINE KINASE INHIBITORS | |
| CN103224496B (en) | Tricyclic antidepressants PI3K and/or mTOR inhibitors | |
| CN104230952B (en) | Compound containing pyrimidine skeleton, and preparation method and use of compound | |
| CN105732616B (en) | Pyrrolopyridines of the amide structure containing biaryl and its preparation method and application | |
| CN103191121B (en) | Two (quinazoline-4-base) diselenide compound is preparing the purposes in cancer therapy drug | |
| CN105153026B (en) | Sorafenib derivative of the amide structure containing biaryl and its preparation method and application | |
| CN107573340B (en) | Preparation and application of 2-carbamoyl-4-arylheteropyridine compounds | |
| CN106831812B (en) | Heterocyclic pyrimidine or pyrazine compound containing biarylamide structure and application thereof | |
| Șandor et al. | Discovery of a novel series of quinazoline–thiazole hybrids as potential antiproliferative and anti-angiogenic agents | |
| Dai et al. | Design, synthesis and biological evaluation of 4-(4-aminophenoxy) picolinamide derivatives as potential antitumor agents | |
| CN109280048A (en) | A kind of pyrimidine compound containing substituted phenylacrylamide structure and its application | |
| CN106810549B (en) | 7- azaindoles and its application containing dihydrogen dazin structure | |
| Xu et al. | Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer | |
| CN101550136B (en) | Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament | |
| CN107151233B (en) | Hydrazone-containing pyrimidine derivative and application thereof | |
| CN116751162B (en) | A quinoline compound, preparation method thereof, pharmaceutical composition and medical use thereof | |
| CN104211682B (en) | Pyridine compounds and their and application thereof | |
| TW202039423A (en) | Analogues of pentamidine and uses therefor | |
| CN112979659B (en) | Preparation and application of HIF-2 alpha small molecule inhibitor | |
| CN109134451A (en) | 1,3- 2-substituted carbamide class and thiourea derivatives and its application | |
| Liu et al. | Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity | |
| CN108358894A (en) | A kind of compound and the preparation method and application thereof of inhibition of histone acetyl transaminase | |
| CN108456165B (en) | Sulfonylurea compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |